Trial Profile
A phase I trial of RM-1929 in patients with recurrent Squamous Cell Head and Neck Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2021
Price :
$35
*
At a glance
- Drugs Cetuximab sarotalocan (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Rakuten Medical
- 08 Jul 2021 Results published in the Rakuten Medical Media Release.
- 08 Jul 2021 According to a Rakuten Medical media release, data from this study was published in the International Journal of Clinical Oncology and published on June 24, 2021.
- 08 Apr 2019 According to a Rakuten Medical media release, based upon the data of this and other phase I/II study, ASP-1929 received Sakigake designation under the Sakigake Designation System, which is a Fast Track designation from the Japanese Ministry of Health, Labour, and Welfare as a treatment for head and neck cancer patients."